Recently, SDIC JULI completed a strategic investment of RMB 450 million in Abiochem Biotechnology (Group) Co., Ltd. (Abiochem), a leading domestic biomanufacturing enterprise. The investment was jointly made by the JULI M&A Fund and JULI Hangshi Fund.

Abiochem has established a comprehensive bioengineering resource library (enzymes, genetic elements, and chassis cells) and synthetic biology technology innovation platforms. It possesses extensive expertise in biosynthesis, high-performance cell factory design, and scaled production, with a complete synthetic biology pathway spanning "enzyme → biosynthetic pathway → smart cell → product creation" and industrial manufacturing capabilities. The company’s diverse product matrix has made it a strategic partner to multiple industry leaders, maintaining competitive advantages in biopharmaceuticals and green agriculture while achieving breakthroughs in nutrition and health. Its functional ingredients—including HMOs (human milk oligosaccharides), steviol glycosides, and sialic acid -- were among the first approved in China.

Advancing SDIC Group’s strategic initiative in biomanufacturing, SDIC JULI continues to invest in the sector. This transaction follows its earlier investment in Moonsun Bio. Moving forward, SDIC JULI will collaborate with Abiochem across biomanufacturing innovation platforms, R&D centers, non-grain feedstock development, and fund investments to consolidate Abiochem’s leadership and generate sustainable economic and social value for stakeholders.

Source: SDIC JULI Official Account